Global Non-melanoma Skin Cancer Market 2014-2018 - Hawaii News Now - KGMB and KHNL

Global Non-melanoma Skin Cancer Market 2014-2018

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE Research and Markets

DUBLIN, June 19, 2014 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Global Non-melanoma Skin Cancer Market 2014-2018" report to their offering.

A current trend witnessed in the Global Non-melanoma Skin Cancer market is the use of combination therapies for the treatment of non-melanoma skin cancer. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and destruction of cancerous cells.

For instance, radiation therapy may be used in combination with other therapies (chemotherapy and surgery) to treat aggressive or recurrent non-melanoma skin cancer. Patients that are non-reactive may react to combination therapy with 0.5 percent tretinoin cream with 5-FU cream. Thicker hypertrophic lesions should be treated first with cryosurgery, gentle curettage, or even primed with applications of tretinoin cream or short courses of topical diclofenac sodium. The combination is chosen according to the size of the tumor and risk of recurrence.

According to the report, the Global Non-melanoma Skin Cancer market is driven by several factors, of which the increasing prevalence of non-melanoma skin cancer resulting from factors such as increased exposure to UV rays, ozone layer depletion, and genetic mutation is one of the major drivers.

Further, the report states that one of the major challenges faced by the market is the availability of alternative treatments such as surgery and non-invasive treatments. Surgery is the most preferred option for the treatment of BCC and SCC as its success rate is 99 percent. These alternative treatments limit the consumption of drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Type

08. Pipeline Analysis

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

18. Non-invasive Treatment Market

19. Key Vendor Analysis

20. Other Reports in this Series

Companies Mentioned:

  • Almirall SA
  • Aqua Pharmaceuticals LLC
  • Biofrontera AG
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Cannabis Science Inc.
  • Cellceutix Corp.
  • Elekta AB
  • Eli Lilly and Co.
  • F. Hoffmann-la Roche Ltd.
  • Galderma SA
  • iCAD Inc.
  • IRX Therapeutics Inc.
  • LEO Pharma A/S
  • Meda AB
  • Merck & Co. Inc.
  • Moberg Pharma AB
  • Mylan Pharmaceutical Inc
  • Novartis International AG
  • Oncothyreon Inc.
  • Sun Pharma Industries Ltd.
  • Valeant Pharmaceuticals Inc.
  • Varian Medical Systems Inc.

For more information visit

Media Contact: Laura Wood, +353-1-481-1716,

©2012 PR Newswire. All Rights Reserved.